


Open Access Webinar Registration now live for Accelerating Patient Access to Innovative Interventions

Free live Webinar from International Market Access Society (IMAS)

BOULDER, CO, UNITED STATES, November 7, 2022 /EINPresswire.com/ -- The International Market Access Society (IMAS) announces open registration for a Webinar on Accelerating Patient Access to Innovative Interventions: Europe's New Approach to Assessment for Reimbursement & Pricing Decisions Compared to the United States.



The graphic features a purple background with white and yellow text. On the right side, the IMAS logo is displayed, consisting of the letters 'IMAS' in a bold, sans-serif font, with a shield icon containing a caduceus symbol. Below the logo, the text 'INTERNATIONAL MARKET ACCESS SOCIETY' is written in a smaller font. To the left of the logo, the main title of the webinar is written in white: 'Accelerating Patient Access to Innovative Interventions: Europe's New Approach to Assessment for Reimbursement & Pricing Decisions Compared to the United States'. Below the title, the slogan 'Reimagine Access. Drive Innovation.' is written in yellow and white. At the bottom of the graphic, the text 'Open access registration now live for November 21 Webinar' is written in white.

This live Webinar will take place on Monday, November 21, 2022 at 10:00 US EST / 16:00 CET for approximately 45 minutes, with 15-20 minutes' Q&A period with the experts.

With the recent adoption of European Regulation on common Health Technology Assessment (HTA), there will be important and far-reaching changes that biopharmaceutical and device companies (and patients) need to understand – not just in the EU, but in all regions of the world.

In this Webinar, we will feature two experts covering the differing approaches of the healthcare systems of the EU and the United States, and how the changes in HTA regulations can affect all parties involved :

- Diana Brixner, RPh, PhD, Professor, Exec Director Pharmacotherapy Outcomes Research Center, Univ of Utah, USA
- Mira Pavlovic, MD, Professor, Director & Founder, Medicines Development and Training (MDT) Services, France

[CLICK HERE TO REGISTER FOR FREE:](#)

Learning Aims:

- Explore relative effectiveness assessment as the basis for reimbursement decisions in Europe
- Understand the current system of voluntary national assessments (HTA Network), and how reimbursement decisions in different EU countries are determined
- Learn the key principles, implementation and consequences for industry, payers, and patients of the forthcoming EU-level joint clinical assessments (JCAs) that will serve as the basis for national value assessments and price negotiations
- Discover the various public and private payers for healthcare in the US, including how reimbursement decisions are made, and who makes them
- Examine the complicated flow of money through healthcare in the US and its many detours on the way from households to providers
- Discuss formulary management options for improving patient access to affordable care, and how stakeholders use the Academy of Managed Care Pharmacy (AMCP) Dossier in decision making

About IMAS

IMAS' vision is to be a global voice to accelerate access to relevant healthcare interventions to patients considering all stakeholders in pricing, reimbursement perspective involved in market access. [CLICK TO LEARN MORE ABOUT IMAS](#) and join for free.

Joel Murray

IMAS

+1 720-465-4921

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/599992710>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.